Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (PROGRESS-AD)

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Phase 2


Alzheimer's Disease


Other: Placebo
Drug: GSK4527226

Study type


Funder types



2023-505083-11-00 (Other Identifier)

Details and patient eligibility


The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.


282 estimated patients




50 to 85 years old


No Healthy Volunteers

Inclusion criteria

Participant must be in the Alzheimer's continuum as defined by the 2018 National Institute on Aging and Alzheimer's Association (NIAAA) Research Framework corresponding to the clinical categories of MCI due to AD and mild AD dementia.

Participant must have evidence of amyloid positivity either by positive positron emission tomography (PET) result (Amyloid PET scans must be read by a central imaging lab) or cerebrospinal fluid (CSF) amyloid beta (Aβ) test result indicative of amyloid positivity

Participants must also meet the following criteria for clinical severity:

  • MMSE score of between 21 and 29 points
  • CDR-global score (GS) of 0.5 to 1.0.
  • CDR Memory Box score greater than or equal to (≥) 0.5.
  • Participants with objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale-IV Logical Memory II (WMS-IV LMII)
  • If the participant is receiving symptomatic AD medications such as an Acetylcholinesterase inhibitor (AChEI) or memantine, the dosing regimen must have been stable for at least 12 weeks prior to screening and is not expected to change during study participation.
  • If the participant is receiving other medications for AD related symptoms or associated conditions, the dosing regimen must have been stable for at least 4 weeks prior to screening and not expected to change during study participation. Symptoms must be considered adequately and stably controlled by the investigator, without marked changes in medication anticipated for the duration of the study.
  • Body weight ≥ 45 kilogram (kg) to less than or equal to (≤)120 kg with body mass index (BMI) between 17 and 34.9 kilogram per meter square (kg/m^2), inclusive.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and if of child-bearing potential follows contraception requirements outlined in the protocol
  • A male participant is eligible to participate if he follows contraception requirements outlined in the protocol
  • Willing and able to give informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Availability of an adult person who has frequent and sufficient contact with the participant is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, and signs the ICF of the study partner.

Exclusion criteria

Participant has evidence of any neurological condition other than AD that may contribute to cognitive impairment.

  • History or presence of vascular disease that has the potential to affect cognitive function.
  • History or presence of stroke within the past 1 year or recent transient ischemic attack within 180 days before screening.
  • History of severe, clinically significant central nervous system (CNS) trauma.
  • History or presence of intracranial tumor.
  • Presence of ongoing infection(s) that may affect brain function, or history of infections that resulted in neurologic sequelae.
  • History of primary psychiatric diagnosis that the investigator considers may interfere with study assessments.

Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, suicidal behaviour or has been assessed to be at risk of suicide, in the opinion of the investigator within 6 months before screening, at screening, or at the Baseline visit, or has been hospitalized or treated for suicidal behaviour in the past 2 years.

Participant has history of alcohol and/or moderate to severe substance use disorder within the past 2 years

Magnetic resonance imaging (MRI) evidence based on central read of:

  • >3 lacunar infarcts.
  • Stroke involving a major vascular territory, severe small vessel, or white matter disease.
  • Any territorial infarct >1 cubic centimetre (cm^3).
  • White matter hyperintense lesions on the FLAIR sequence that correspond to an overall Fazekas score of 3
  • >4 microhaemorrhages.
  • Any areas of superficial (leptomeningeal) hemosiderosis.
  • A single macro-hemorrhage greater than 10 millimetres (mm) at greatest diameter.
  • Vasogenic edema.
  • Cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions.
  • Space occupying lesions or brain tumors.
  • Significant cerebral vascular pathology
  • History suggestive of exposure to, or past tuberculosis (TB) infection should undergo screening for TB disease.
  • Chronic active immune disorder requiring systemic immunosuppressive therapy within 6 months prior to Screening.
  • Screening serum vitamin B12 concentration < Lower limit of normal (LLN) or in the low normal range
  • Folate <LLN or Thyroid-stimulating hormone (TSH) > Upper limit of normal (ULN)
  • Hemoglobin A1c >8 percentage (%) or poorly controlled diabetes during the last 12 weeks
  • History of cancer
  • Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
  • Planned surgery during the study which requires general, spinal, or epidural anesthesia that would take place during the study.

Key exclusionary medications include:

  • Antipsychotics, opiates/opioids, cannabinoids, hypnotics, antidepressants, mood stabilizers, or stimulants that are used on a chronic basis, are exclusionary if not consistent with the following rule: treatment has to have been at a stable dose for at least 4 weeks before screening and should remain stable during the study
  • Any biologic drugs with systemic exposure, whether investigational or approved, used within 6 months before screening Any disease modification drug for AD, such as aducanumab and lecanemab, whether investigational or approved, used within 6 months before screening.
  • Anticoagulation medications within 90 days of screening and during the study
  • Systemic immunosuppressive therapy within 90 days before screening and during the study.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

282 participants in 3 patient groups, including a placebo group

GSK4527226 Dose 1
Experimental group
Participants will receive GSK4527226 Dose 1
Drug: GSK4527226
GSK4527226 Dose 2
Experimental group
Participants will receive GSK4527226 Dose 2
Drug: GSK4527226
Placebo Comparator group
Participants will receive placebo.
Other: Placebo

Trial contacts and locations



Central trial contact

EU GSK Clinical Trials Call Center; US GSK Clinical Trials Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems